{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:18:29Z","timestamp":1792034309976,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jlr.2025.100857","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:32:15Z","timestamp":1751661135000},"page":"100857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Repurposing daclatasvir for MASLD Therapy\u2014A promising step forward with challenges ahead"],"prefix":"10.1016","volume":"66","author":[{"given":"Carlos Jose","family":"Pirola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2025.100857_bib1","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.cell.2024.05.009","article-title":"Resmetirom for treatment of MASH","volume":"187","author":"Sookoian","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jlr.2025.100857_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jlr.2025.100857_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3350\/cmh.2020.0136","article-title":"Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology","volume":"26","author":"Sookoian","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.jlr.2025.100857_bib4","doi-asserted-by":"crossref","first-page":"100835","DOI":"10.1016\/j.jlr.2025.100835","article-title":"Hepatoprotective drug screening identifies daclatasvir a promising therapeutic candidate for MASLD by targeting PLIN2","volume":"66","author":"Shu","year":"2025","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2025.100857_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43162-023-00197-1","article-title":"The effect of different direct antivirals on hepatic steatosis in nondiabetic and na\u00efve hepatitis C-infected Egyptian patients","volume":"35","author":"El-Ghandour","year":"2023","journal-title":"Egypt J. Intern. Med."},{"key":"10.1016\/j.jlr.2025.100857_bib6","doi-asserted-by":"crossref","DOI":"10.5501\/wjv.v13.i1.90384","article-title":"Perilipin 2 inhibits replication of hepatitis B virus deoxyribonucleic acid by regulating autophagy under high-fat conditions","volume":"13","author":"Delpino","year":"2024","journal-title":"World J. Virol."},{"key":"10.1016\/j.jlr.2025.100857_bib7","article-title":"A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice","volume":"6","author":"Scorletti","year":"2024","journal-title":"JHEPReport"},{"key":"10.1016\/j.jlr.2025.100857_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167045","article-title":"Exercise ameliorates lipid droplet metabolism disorder by the PLIN2\u2013LIPA axis-mediated lipophagy in mouse model of non-alcoholic fatty liver disease","volume":"1870","author":"Fang","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.jlr.2025.100857_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41366-021-00955-7","article-title":"Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist","volume":"46","author":"Pontes-da-Silva","year":"2022","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.jlr.2025.100857_bib10","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.jlr.2024.100635","article-title":"Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models","volume":"65","author":"Wang","year":"2024","journal-title":"J. Lipid Res."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227525001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227525001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:14:38Z","timestamp":1756480478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227525001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0022227525001191"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2025.100857","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing daclatasvir for MASLD Therapy\u2014A promising step forward with challenges ahead","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2025.100857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"100857"}}